Transforming the scientific, health care, and sociopolitical culture of an entire country through clinical research: The story of GISSI

American Heart Journal

Volumn 148, Issue 2, 2004, Pages 193-195

  Yusuf, Salim ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; FIBRINOLYTIC AGENT; HEPARIN; OMEGA 3 FATTY ACID; STREPTOKINASE;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL RESEARCH; CLINICAL TRIAL; CORONARY CARE UNIT; DRUG INDUSTRY; EDITORIAL; FIBRINOLYTIC THERAPY; HEALTH CARE PLANNING; HEALTH CARE SYSTEM; HEART FAILURE; HEART INFARCTION; HUMAN; MEDICAL RESEARCH; MORTALITY; PATIENT CARE; POLITICS; PRIORITY JOURNAL; RISK FACTOR; SOCIAL ASPECT;

BIOMEDICAL RESEARCH; CARDIOVASCULAR DISEASES; CLINICAL TRIALS; EPIDEMIOLOGIC STUDIES; FIBRINOLYTIC AGENTS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; ITALY; META-ANALYSIS; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS; STREPTOKINASE; THROMBOLYTIC THERAPY;

EID: 4143112434     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ahj.2004.03.056     Document Type: Editorial

References (17)

1. Yusuf S., Reddy S., Ôunpuu S., et al. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation. 104:2001;2746-2753
2. Kannel WB, Castelli WP, Revotskie N, et al. Profile of the coronary-prone individual. Assessment of risk of developing coronary heart disease: The Framingham Study. Proc Annu Meet Med Sect Am Life Conv 1967;55:74-99
3. Doll R, Peto R, Wheatley K, et al. Mortality in relation to smoking: 40 years' observations on male British doctors. BMJ 1994;309:901-11
4. Marmot MG, Shipley MJ, Rose G. Inequalities in death - specific explanations of a general pattern? Lancet 1984;1:1003-6
5. Hjalmarson A., Herlitz J., Holmberg S., et al. The Goteborg metoprolol trial. Effects on mortality and morbidity in acute myocardial infarction. Circulation. 67:1983;I26-32
6. Yusuf S., Collins R., Peto R. Why do we need some large, simple randomized trials? Stats Med. 3:1984;409-420
7. Yusuf S., Peto R., Lewis J., et al. Beta blockade during and after myocardial infarction an overview of the randomized trials. Prog Cardiovasc Dis. 27:1985;335-371
8. Chalmers TC, Matta RJ, Smith H Jr, et al. Evidence favoring the use of anticoagulants in the hospital phase of acute myocardial infarction. N Engl J Med 1977;297:1091-6. PMID: 909566 [PubMed - indexed for MEDLINE]
9. ISIS-1 (First International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction ISIS-1. Lancet. i:1986;57-66
10. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction ISIS 2. Lancet. I:1988;349-360
11. GISSI. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarcto Miocardicao (GISSI). Lancet 1986;1:397-402
12. Tavazzi L, Maggioni A, Tognoni G. Participation versus education: the GISSI story and beyond. Am Heart J 2004;148:222-9
13. Gruppo Italiano per lo Studio Della Sopravvivenza Nell'Infarto Miocardico. GISSI-2: a factorial randomized trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet 1990;336:65-71
14. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3 a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet. 339:1992;1-18
15. GISSI-Prevenzione. Dietary supplementation within n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio dell Soppravvivenza nell'Infarcto Miocardico. Lancet 1999;354:447-55
16. The Heart Outcomes Prevention Evaluation Study Investigators. Vitamin E supplementation and cardivascular events in high-risk patients. N Engl J Med. 342:2000;154-160
17. Tu K., Mamdani M.M., Jacka R.M., et al. The striking effect of the Heart Outcomes Prevention Evaluation (HOPE) on ramipril prescribing in Ontario. CMAJ. 168:2003;553-557